Advancements in Treatment of Refractory and Relapsed Myeloid Sarcoma

Sahu, Kamal Kant; Mishra, Ajay Kumar; Lal, Amos

doi:10.1200/jop.19.00447

Cited by 4 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding local treatment, several studies have revealed that surgery or RT can shrink tumors, relieve local symptoms, and sometimes aid in diagnosis; however, they do not affect survival ( 24 – 26 ). In addition, as MS molecular mechanism’s understanding improves, targeted therapy is also on the horizon ( 27 , 28 ).…”

Section: Discussionmentioning

confidence: 99%

Incidence, clinical characteristics, and prognostic nomograms for patients with myeloid sarcoma: A SEER-based study

Xing

Zhu

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundMyeloid sarcoma (MS) is a rare hematological tumor that presents with extramedullary tumor masses comprising myeloid blasts. A controversial issue is whether MS involving normal hematopoietic sites (liver, spleen, and lymph nodes) should be excluded in future studies. We aimed to compare MS characteristics and outcomes involving hematopoietic and non-hematopoietic sites and construct a prognostic nomogram exclusively for the latter.MethodsData from patients diagnosed with MS between 2000 and 2018 were collected from the Surveillance, Epidemiology, and End Results (SEER) database. According to the primary site, patients were classified as having MS involving hematopoietic sites (hMS) or non-hematopoietic sites (eMS). Clinical characteristics and survival outcomes were compared between the two groups using Wilcoxon, chi-square, and log-rank tests. Cox regression analysis was used to identify eMS prognostic factors to establish prognostic nomograms. The models’ efficiency and value were assessed using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).ResultsIn total, 694 patients were enrolled, including 86 with hMS and 608 with eMS. There were no sex, race or marital status distribution differences between the two groups. Patients with eMS had better overall and cancer-specific survival rates than those with hMS. Additionally, prognostic factor effects differed between the two groups. Patients with eMS were randomly divided into the training (number of patiens, n=425) and validation cohorts (n=183). Age, first primary tumor, primary site, and chemotherapy were used to establish nomograms. The C-index values of overall survival (OS) and cancer-specific survival (CSS) nomograms were 0.733 (validation: 0.728) and 0.722 (validation: 0.717), respectively. Moreover, ROC, calibration curves, and DCA confirmed our models’ good discrimination and calibration ability and potential clinical utility value.ConclusionOur study described the differences between patients with eMS and those with hMS. Moreover, we developed novel nomograms based on clinical and therapeutic factors to predict patients with eMS’ 1-, 3- and 5-year survival rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence, clinical characteristics, and prognostic nomograms for patients with myeloid sarcoma: A SEER-based study

Xing

Zhu

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The management of such hematologic malignancies relies on intensive chemotherapy that is sometimes followed by AHSCT, even if the global treatment strategy for these lesions is currently not well established [7]. However, some patients with refractory disease or chronic conditions that are not suitable for intensive chemotherapy may benefit from targeted therapeutics such as venetoclax [3] or midostaurin [8]. We note in this regard that our patient was resistant to a combination of midaustorin and 5-azacytidine.…”

Section: Discussionmentioning

confidence: 99%

Successful nelarabine and venetoclax treatment of a relapsed/refractory mediastinal myeloid sarcoma with clonal TCR rearrangement

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Other hematological conditions like myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), and myelofibrosis (MF) are also reported to have leukemic deposits. MS commonly involves lymph nodes, skin, head and neck region, and orbit although almost any site may be involved (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13). Gastrointestinal involvement is very rare site of MS. Gallbladder is even more rare to involve and often confused with other common gallbladder pathologies like cholecystitis, gallbladder cancer etc.…”

Section: Introductionmentioning

confidence: 99%

Review on gall bladder myeloid sarcoma: a great masquerader

2020

Self Cite

View full text Add to dashboard Cite

Pain in abdomen has wide differentials and narrowing down the clinical possibilities depends on type of pain, location, characterization which is usually assisted by imaging studies. Cholecystitis and cholelithiasis are amongst the common causes of acute abdomen. This study reviews the literature for the clinical characteristics, differential diagnosis, treatment and prognosis of reported cases of gallbladder myeloid sarcoma (GB-MS) who presented with abdominal symptoms. A total of 17 cases of GB-MS were studied. The median age was 52 years with age range of 23 to 84 years. All except 1 patient presented with abdominal symptoms. Based on imaging or pathological studies, 3 cases were initially confused with gallbladder lymphoma or cancer. Only 5 patients were treated with AML like chemotherapy. Treatmentgiven included combinations of surgery, chemotherapy, and radiotherapy. None of the cases underwent HSCT for GB-MS. Seven patients were alive till the time of last F/U, 9 succumbed to death while F/U of 1 patient was not available. Irrespective of treatment protocol followed suggesting the poor prognosis in GB-MS cases. In conclusion, acute abdomen complicating blood malignancies is life threatening and can be devastating if not detected and treated in a timely fashion.

show abstract

Advancements in Treatment of Refractory and Relapsed Myeloid Sarcoma

Cited by 4 publications

References 15 publications

Incidence, clinical characteristics, and prognostic nomograms for patients with myeloid sarcoma: A SEER-based study

Incidence, clinical characteristics, and prognostic nomograms for patients with myeloid sarcoma: A SEER-based study

Successful nelarabine and venetoclax treatment of a relapsed/refractory mediastinal myeloid sarcoma with clonal TCR rearrangement

Review on gall bladder myeloid sarcoma: a great masquerader

Contact Info

Product

Resources

About